M Gervin1, S Browne, J Garavan, M Roe, C Larkin, E O'Callaghan. 1. The Theodore and Vada Stanley Research Unit, Cluain Mhuire Service, Hospitaller Order St John of God, Newtownpark Avenue, Blackrock, Co. Dublin, Ireland.
Abstract
OBJECTIVE: Subjective reports of dysphoric responses to neuroleptic medication are common in clinical practice. However, cognitive and affective side effects of neuroleptic medications are difficult to differentiate from the symptoms of schizophrenia. We sought to elucidate the relative contribution of extrapyramidal side effects and symptomatology to dysphoric response. METHOD: Fifty clinically stable outpatients with schizophrenia attending a rehabilitation centre were assessed for extrapyramidal side effects and symptomatology before completing the drug attitude inventory (DAI). RESULTS: Presence of extrapyramidal side effects, found in 28 patients (Z = -1.99, p = 0.05), and severity of negative symptoms (r = -0.47, p = 0.001) were independently associated with dysphoric response, explaining a significant proportion of the variance (R = 0. 53, R(2) = 25.2%, F = 9.27, df = 2, p = 0.0004). CONCLUSIONS: Patients who report a dysphoric response which they associate with neuroleptic medications have more extrapyramidal side effects and more severe negative symptoms. While these responses may be part of the negative symptoms of the illness or due to other factors such as depression, we raise the possibility that they may be clinically indistinguishable from, and be a subjective measure of, the so-called 'neuroleptic-induced deficit syndrome'.
OBJECTIVE: Subjective reports of dysphoric responses to neuroleptic medication are common in clinical practice. However, cognitive and affective side effects of neuroleptic medications are difficult to differentiate from the symptoms of schizophrenia. We sought to elucidate the relative contribution of extrapyramidal side effects and symptomatology to dysphoric response. METHOD: Fifty clinically stable outpatients with schizophrenia attending a rehabilitation centre were assessed for extrapyramidal side effects and symptomatology before completing the drug attitude inventory (DAI). RESULTS: Presence of extrapyramidal side effects, found in 28 patients (Z = -1.99, p = 0.05), and severity of negative symptoms (r = -0.47, p = 0.001) were independently associated with dysphoric response, explaining a significant proportion of the variance (R = 0. 53, R(2) = 25.2%, F = 9.27, df = 2, p = 0.0004). CONCLUSIONS:Patients who report a dysphoric response which they associate with neuroleptic medications have more extrapyramidal side effects and more severe negative symptoms. While these responses may be part of the negative symptoms of the illness or due to other factors such as depression, we raise the possibility that they may be clinically indistinguishable from, and be a subjective measure of, the so-called 'neuroleptic-induced deficit syndrome'.
Authors: Steven M Grauer; Radka Graf; Rachel Navarra; Amy Sung; Sheree F Logue; Gary Stack; Christine Huselton; Zhi Liu; Thomas A Comery; Karen L Marquis; Sharon Rosenzweig-Lipson Journal: Psychopharmacology (Berl) Date: 2008-12-20 Impact factor: 4.530
Authors: Alex Hofer; Maria A Rettenbacher; Christian G Widschwendter; Georg Kemmler; Martina Hummer; W Wolfgang Fleischhacker Journal: Eur Arch Psychiatry Clin Neurosci Date: 2005-11-29 Impact factor: 5.270
Authors: Alejandro Szmulewicz; Cecilia Samamé; Pablo Caravotta; Diego J Martino; Ana Igoa; Diego Hidalgo-Mazzei; Francesc Colom; Sergio A Strejilevich Journal: Int J Bipolar Disord Date: 2016-02-16